300294 China Resources Boya Bio-pharmaceutical Group
- 34.47
- -0.05-0.14%
China Resources Boya Bio-pharmaceutical Group News
Liberal Arts Biotech (300294): Steady management of the blood products business, spin-off of the non-blood products business and lightweight launch
Core view On April 23, the company released its 2024 quarterly report. After excluding the non-blood products business, the company's blood products business maintained steady growth. The issuance of 24Q1 albumin and fibrin batches increased steadily, while the issuance of static and propylene batches declined year-on-year, mainly
Liberal Arts Biotech (300294): Performance is in line with expectations, profitability improved significantly
Incident: [Business Administration BLFa E_Sum20mA4rqy] 1 quarterly report, 2024Q1 achieved operating income of 448 million yuan, a year-on-year decrease of 44.36%; net profit to mother was 152 million yuan, a year-on-year decrease
Liberal Arts Biotech (300294): Performance is in line with expectations, optimistic about the company's future growth space
Core idea: The company released its 2024 quarterly report. 2024Q1 achieved revenue of 448 million yuan (-44.36%, the following are year-on-year figures), net profit to mother of 152 million yuan (-10.74%),
China Post Securities released a research report on April 25 stating that it gave Liberal Arts Biotech (300294.SZ) a purchase rating. The main reasons for the rating include: 1) blood products are expected to maintain good growth, and the amount of pulp c
China Post Securities released a research report on April 25 stating that it gave Liberal Arts Biotech (300294.SZ) a purchase rating. The main reasons for the rating include: 1) blood products are expected to maintain good growth, and the amount of pulp collected is expected to increase further throughout the year; 2) excellent profitability, and the products under development are progressing steadily. (Mainichi Keizai Shimbun)
Liberal Arts Biotech (300294): Divestment of a subsidiary focusing on blood products led to fluctuations in performance
The 1Q24 results are in line with our expectations. The company announced 1Q24 results: revenue of 448 million yuan, down 44.36% year on year; net profit to mother was 152 million yuan, down 10.74% year on year, corresponding to earnings per share of 0.30
China Resources Pharmaceutical (03320): China Resources Liberal Arts Biotech's net profit for the first quarter of 152.2 million yuan decreased by 12.97% year-on-year
China Resources Pharmaceuticals (03320) announced that China Resources Biotech, a subsidiary of the company, will be 3 as of March 31, 2024...
Liberal Arts Biotech (300294): First-quarter results are in line with expectations, annual pulp harvesting is expected to increase at an accelerated pace
Incident: On April 24, the company released its 2024 quarterly report: the company achieved revenue of 448 million yuan, a year-on-year decrease of 44.36%; realized net profit of 152 million yuan, a year-on-year decrease of 10.74%; realized a year-on-year deduction
Liberal Arts Biotech (300294.SZ) announced first-quarter results, net profit of 152 million yuan, a decrease of 10.74%
Liberal Arts Biotech (300294.SZ) released its report for the first quarter of 2024, achieving 4.4 operating income during the reporting period...
Liberal Arts Biotech (300294.SZ) plans to pay 3 yuan for 10 shares to be deducted from interest on April 26
Liberal Arts Biotech (300294.SZ) announced that the company's 2023 equity distribution plan: every 10...
Liberal Arts Biotech (300294): Steady growth in blood products focuses on achieving breakthroughs in the main business
Incident Liberal Arts Biotech Co., Ltd. released its 2023 annual report: achieved revenue of 2,652 billion yuan in 2023, a year-on-year decrease of 3.87%; realized net profit to mother of 237 million yuan, a year-on-year decrease of 45.06%; net profit not attributable to mother
Liberal Arts Biotech (300294): Actively expand plasma supply and divest the non-blood products business and launch a lightweight business
Incident: The company announced its 2023 annual report, achieving operating income of 2,653 billion yuan (-3.87%), net profit to mother of 237 million yuan (-45.06%), and net profit not attributable to mother of 143 million yuan (-63.
Liberal Arts Biotech (300294.SZ): In 2023, the company's VIII factor and PCC sales trends were good, and overall sales grew rapidly
Gelonghui, April 2, 丨 Boya Biotech (300294.SZ) was surveyed by a specific target on April 1, 2024. Regarding “the sales situation of the company's factor VIII, PCC and other products,” the company replied that in 2023, the company's sales trend of Factor VIII and PCC was good, and overall sales were growing rapidly. According to hospital CPA sample statistics, the company's prothrombin complex (PCC) ranks third in the industry. The company attaches importance to building an academic system and continuously improving product coverage and penetration rate.
Liberal Arts Biotech (300294.SZ): In 2023, the company collected 467.3 tons of pulp, an increase of 6.47% over the previous year
Gelonghui, April 2, 丨 Boya Biotech (300294.SZ) was surveyed by specific subjects on April 1, 2024. Regarding “the company's pulp collection situation and future trends,” the company replied that in 2023, the company's pulp collection volume was 467.3 tons, an increase of 6.47% over the previous year. There was a negative year-on-year increase in pulping volume from January to July 2023, but positive year-on-year growth was achieved since August, showing a trend of low and high levels. Overall, the performance of pulp collection is steady and improving. The company focuses on the business policy of “setting goals, setting standards, heavy rewards and penalties, and strong execution”, innovates the new development model and thoroughly implements “new development”
Liberal Arts Biotech (300294): Steady growth in blood products business, impairment of goodwill affects apparent profit
Core idea: The company publishes its 2023 annual report. In 2023, the company achieved revenue of 2,652 billion yuan (-3.87%, the following are year-on-year values), net profit to mother of 237 million yuan (-45.06%), deducted from non-payment
Liberal Arts Biotech (300294): Steady growth in blood products business continues to focus on main business development
Core view On March 22, the company released its 2023 annual report, and the performance was in line with expectations. The company's blood products business achieved steady growth in 2023, the amount of pulp collected continued to increase, breakthroughs were made in pulp station resources and R&D pipelines, Fuda Pharmaceutical and
Liberal Arts Biotech (300294): Blood products business is growing steadily, and the product echelon continues to be rich
Incident: The company released its 2023 annual report, achieving operating income of 2,652 million yuan, -3.87%; net profit to mother of 237 million yuan, or -45.06% year-on-year; net profit after deducting non-return to mother of 143 million yuan, year-on-year
Liberal Arts Biotech (300294.SZ): The price of the company's products is stable
On March 27, Gelonghui Biotech (300294.SZ) said on the investor interactive platform that the price of the company's products is stable. The cost of intravenous human immunoglobulin increased by 16.68% in 2023, mainly due to the increase in the revenue scale of this product.
Liberal Arts Biotech (300294): Steady growth in the blood products business, gradually promoting the divestment of the non-blood business
Net profit for 2023 is lower than our expectations. The company announced the results for 2023: revenue of 2,652 billion yuan, down 3.87% year on year; net profit to mother was 237 million yuan, corresponding to profit of 0.47 yuan per share, down 4 years on year
China Resources Pharmaceuticals (03320.HK): Liberal Arts Biotech achieved net profit of 237 million yuan in 2023 and plans to pay 10 to 3 yuan
On March 25, Ge Longhui Pharmaceutical (03320.HK) announced that in 2023, Liberal Arts Biotech (300294.SZ) achieved operating income of RMB 2,652 billion, down 3.87% year on year; net profit attributable to shareholders of Liberal Arts Biotech was 237 million yuan, down 45.06% year on year; net profit attributable to shareholders of Liberal Arts Biotech after deducting non-recurring profit and loss was 143 million yuan, down 63.51% year on year; basic income per share is 0.47 yuan; it plans to distribute a cash dividend of 3 yuan (tax included) for every 10 shares to all shareholders.
Commentary on the 2023 Annual Report of Liberal Arts Biotech (300294): Continued focus on the core business of blood products to strengthen plasma station resource expansion and acquisition integration
Performance Overview: The company's revenue in 2023 was 2,652 billion yuan (-3.87%); net profit to mother was 237 million yuan (-45.06%), mainly due to goodwill impairment preparations of 2.98 billion yuan formed by calculating the acquisition of Nanjing Xinbai
Analysis
Price Target
No Data
